Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
|
|
Post comment
by Anders Olsen, Reed F. Beall, Ryan P. Knox, Sean S. Tu, Aaron S. Kesselheim, William B. Feldman Background Insulin is the primary treatment for type 1 and some type 2 diabetes but remains costly in the United States, even though it was discovered more than a century ago. High prices can lead to nonadherence • Read More »